NDA 207921 · Norton Waterford
Qvar Redihaler
Beclomethasone Dipropionate · Inhalation
Last checked: Nov 20, 2026Latest source record: Sep 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Aug 3, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
196
79 Phase 3, 14 recruiting
FAERS reports
2,861
697 serious, 37 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 30, 2025.
QVAR REDIHALER is indicated in the maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. Limitations of Use: QVAR REDIHALER is not indicated for the relief of acute bronchospasm. QVAR REDIHALER is a corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm. ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- QVAR REDIHALER · BECLOMETHASONE DIPROPIONATE 0.04MG/INH · AEROSOL, METERED, INHALATION · Prescription
- QVAR REDIHALER · BECLOMETHASONE DIPROPIONATE 0.08MG/INH · AEROSOL, METERED, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Beclomethasone Dipropionate" as an intervention, any sponsor and status, largest first.
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPDPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT04320342 · 3,406 participants · Start Apr 27, 2022 · Primary completion Jan 12, 2026
Drug: Beclomethasone Dipropionate; Glycopyrronium Bromide and 1 more · For: COPD; COPD Exacerbation
Sites: Birmingham, Alabama; Dothan, Alabama; Foley, Alabama · 436 sites in all
- Individualizing Treatment for Asthma in Primary Care (Full Study)Pivotal-lookingRecruiting
DARTNet InstituteGovernment (non-federal)
NCT07052942 · 3,200 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 15, 2029
Drug: Inhaled corticosteroid (ICS); Azithromycin · For: Asthma; Asthma Attack; Asthma Exacerbations
Sites: Aurora, Colorado; Orlando, Florida; Kansas City, Kansas · 13 sites in all
- Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)Pivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT00861926 · 1,714 participants · Start Mar 20, 2009 · Primary completion Dec 7, 2010
Drug: Salbutamol; Beclomethasone dipropionate + Formoterol · For: Asthma
Sites: Burgas, Bulgaria; Pleven, Bulgaria; Plovdiv, Bulgaria · 206 sites in all
- Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00254956 · 1,568 participants · Start Jan 2004 · Primary completion Jun 2005
Drug: ciclesonide (XRP1526) · For: Respiratory Tract Diseases; Respiratory Hypersensitivity; Asthma
Sites: Chilly-Mazarin, France
- Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INHPivotal-lookingCompleted
Aurobindo Pharma LtdIndustry
NCT04051710 · 1,550 participants · Start Mar 12, 2019 · Primary completion Aug 29, 2019
Drug: Test Product; Reference Product and 1 more · For: Bronchial Asthma
Sites: Pune, India
Chiesi Farmaceutici S.p.A.Industry
NCT02467452 · 1,479 participants · Start May 2015 · Primary completion Jan 2017
Drug: BDP/FF/GB; FlF/VI + Tiotropium · For: Chronic Obstructive Pulmonary Disease
Sites: Gödöllő, Hungary
- TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)Pivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT02676089 · 1,437 participants · Start Apr 6, 2016 · Primary completion May 28, 2018
Drug: CHF 5993 200/6/12.5 µg; CHF 1535 200/6 µg and 1 more · For: Asthma
Sites: Buenos Aires, Argentina; CABA, Argentina; Mar del Plata, Argentina · 244 sites in all
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled CorticosteroidPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT05292586 · 1,377 participants · Start Aug 31, 2022 · Primary completion Jun 24, 2024
Drug: Beclomethasone Dipropionate/Formoterol Fumarate; Beclomethasone Dipropionate · For: Asthma
Sites: Mobile, Alabama; Chandler, Arizona; Encinitas, California · 91 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective393
- asthma346
- dyspnoea324
- cough265
- device malfunction255
- device delivery system issue194
- device issue178
- product use in unapproved indication126
- headache125
- wrong technique in product usage process112
- product dose omission issue108
- fatigue99
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 355 |
| 2019 | 475 |
| 2020 | 349 |
| 2021 | 308 |
| 2022 | 349 |
| 2023 | 282 |
| 2024 | 331 |
| 2025 | 235 |
| 2026 | 174 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Qvar Redihaler (Beclomethasone Dipropionate)
2024 spending
$72.5M
Beneficiaries
83,367
222,782 claims
Per beneficiary
$870
$23.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $59,157,028 |
| 2021 | $52,807,432 |
| 2022 | $48,407,638 |
| 2023 | $48,874,607 |
| 2024 | $72,512,833 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of various corticosteroids in the treatment of children with allergic rhinitis: A systematic review and network meta-analysis.
Li Y, Xiong J, Zhang Z, et al. · J Evid Based Med 2024 · Systematic Review, Network Meta-Analysis
- Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS, Haeussler K, Czira A, et al. · Adv Ther 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Beclomethasone dipropionate and oropharyngeal candidiasis.
Milne LJ, Crompton GK · Br Med J 1974 · Clinical Trial
- Effect of rhinophototherapy on nasal congestion in patients with seasonal allergic rhinitis.
Karali E, Gunes A, Ural A, et al. · Acta Otorhinolaryngol Ital 2021 · Randomized Controlled Trial
- Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Manguso F, Bennato R, Lombardi G, et al. · PLoS One 2016 · Meta-Analysis, Systematic Review
- Hypothalamic-pituitary-adrenal axis suppression and intranasal corticosteroid use: A systematic review and meta-analysis.
Sampieri G, Namavarian A, Lee JJW, et al. · Int Forum Allergy Rhinol 2022 · Meta-Analysis, Systematic Review
Sponsor: Norton Waterford
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.